Valuation: Haleon plc

Market Cap 29.74B 40.08B 35.66B 32.72B 55.98B 3,789B 57.23B 390B 156B 2,005B 150B 147B 6,347B P/E 2026 *
17.7x
P/E 2027 * 15.7x
Enterprise Value 36.87B 49.68B 44.21B 40.56B 69.4B 4,696B 70.94B 484B 194B 2,485B 186B 182B 7,868B EV / Sales 2026 *
3.27x
EV / Sales 2027 * 3.11x
Free-Float
98.26%
Yield 2026 *
2.38%
Yield 2027 * 2.58%
1 day+3.69%
1 week-10.21%
Current month+5.70%
1 month+2.83%
3 months-6.82%
6 months-1.89%
Current year-9.93%
1 week 310.5
Extreme 310.5
339.3
1 month 310.5
Extreme 310.5
433.6
Current year 310.5
Extreme 310.5
433.6
1 year 310.5
Extreme 310.5
433.6
3 years 274.4
Extreme 274.4
433.6
5 years 241.17
Extreme 241.1735
433.6
10 years 241.17
Extreme 241.1735
433.6
Manager TitleAgeSince
Chief Executive Officer 59 21/07/2021
Director of Finance/CFO 58 31/10/2024
Chief Tech/Sci/R&D Officer 63 31/07/2025
Director TitleAgeSince
Director/Board Member 59 22/05/2022
Chairman 71 31/12/2025
Director/Board Member 59 17/07/2022
Date Insider Type Main position Quantity % Market Cap. Importance
22/09/26 Buy 2,139 0.0000%
22/09/26 Buy 12,209 0.0001%
22/09/26 Buy

Chief Financial Officer

2,317 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+3.69%-10.21%-5.62%+5.37% 38.48B
+0.61%+10.62%+58.16%+149.73% 1,255B
+3.81%+2.82%+48.35%+82.58% 641B
+3.09%+2.95%+39.10%+108.48% 505B
+1.25%-0.78%+52.56%+66.87% 381B
+3.93%+6.02%+82.28%+45.44% 357B
+2.10%+4.26%+34.93%+61.10% 303B
+1.92%+9.37%+13.43%+36.55% 286B
+3.73%+6.82%+61.48%+77.31% 249B
+4.19%+9.68%+42.96%+113.85% 208B
Average +1.98%+1.31%+42.76%+74.73% 422.37B
Weighted average by Cap. +1.16%+3.74%+50.10%+96.95%

Financials

2026 *2027 *
Net sales 11.29B 15.21B 13.54B 12.42B 21.25B 1,438B 21.73B 148B 59.27B 761B 57.01B 55.86B 2,410B 11.68B 15.74B 14B 12.85B 21.98B 1,488B 22.47B 153B 61.3B 787B 58.97B 57.78B 2,493B
Net income 1.67B 2.25B 2B 1.84B 3.14B 213B 3.21B 21.89B 8.76B 112B 8.43B 8.26B 356B 1.83B 2.46B 2.19B 2.01B 3.44B 233B 3.52B 23.97B 9.59B 123B 9.23B 9.04B 390B
Net Debt 7.13B 9.6B 8.55B 7.84B 13.42B 908B 13.71B 93.47B 37.41B 480B 35.99B 35.26B 1,521B 6.58B 8.87B 7.89B 7.24B 12.38B 838B 12.66B 86.28B 34.53B 443B 33.22B 32.55B 1,404B
Projected Income Statement - Annual - Haleon plc
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (31.4%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - pain relief medicines (23.2%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - respiratory medicines (17%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (15.3%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.; - medicines for digestive health (8.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - other (4.2%). Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.6%), North America (35.1%), and Asia/Pacific (23.3%).
Employees
24,535
Date Price Change Volume
04/11/26 GBX 337.60 +3.69% 41,581,767
03/11/26 GBX 325.60 +0.74% 37,215,618
02/11/26 GBX 323.20 +1.19% 68,119,225
30/10/26 GBX 319.40 +0.54% 43,458,476
29/10/26 GBX 317.70 -15.05% 99,147,626
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Haleon plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.376GBP
Average target price
3.784GBP
Spread / Average Target
+12.08%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Haleon plc